Eczema Therapeutics Market, by Treatment (Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin inhibitors, Antibiotics, Immunomodulators, and Interleukin inhibitors), by Distribution Channel (Hospital and Clinics, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Sep 2021

Code : CMI4630

Pages :176

Formats :

Excel and PDF

Industry : Pharmaceutical

Eczema Therapeutics MarketSize and Trends

The global eczema therapeutics market is estimated to be valued at US$ 15,453.4 Mn in 2021 and is expected to exhibit a CAGR of 11.1% over the forecast period (2021-2028).

Figure 1: Global Eczema Therapeutics Market Share, (%), Analysis, By Treatment, 2021

Increasing research and development activities by the market players for developing the treatment for eczema is expected to drive the growth of the global eczema therapeutics market over the forecast period.

Market players are involved in research and development activities for developing the treatment for eczema. This is expected to increase the growth of the market over the forecast period. For instance, in 2020, Pfizer Inc. announced positive Phase III results for its investigational drug, Abrocitinib, an oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of atopic dermatitis or eczema in adults.

Market players are indulged in receiving approvals for the drugs indicated for the treatment of eczema or atopic dermatitis. This is expected to increase the growth of the global eczema therapeutics market over the forecast period.

Increasing approvals from the regulatory authorities are expected to increase the growth of the market over the forecast period. For instance, on June 25, 2021, AbbVie Inc., received approval from the European Medicines Agency\'s (EMA) Committee for Medicinal Products for Human Use (CHMP), for its drug RINVOQ (upadacitinib), an oral, selective, and reversible JAK inhibitor, for the expanded use in adults and adolescents suffering from moderate to severe atopic dermatitis.